A 36-week study evaluating the efficacy as well as subject satisfaction and psychological well-being with increasing doses of abobotulinumtoxinA (ABO, Dysport) found significant and sustained improvement (up to 36 weeks) in glabellar line severity and high patient satisfaction rates.
The Phase 2, multicenter, randomized, dose-ranging, double-blind, placebo-controlled study, published in the Journal of Cosmetic Dermatology (April 2022), included 399 adults with moderate to severe glabellar lines who received either a single ABO treatment dosed at 50, 75, 100 or 125 U, or placebo.
The subjects' glabellar lines were assessed using the investigator live assessment (ILA) photographic scale and subject self-assessment (SSA) static categorial scale (ranging from mild to severe). The researchers also recorded global aesthetic improvement scale (GAIS) grade, FACE-Q appraisal of lines, psychological well-being and age and subject satisfaction grading at baseline and during follow-ups at day 2, week 1, and week 2, and then every four weeks from Week 4 through Week 36. The SSA responder rate was defined as those achieving ≥1-grade improvement in glabellar line severity from baseline at maximum frown.
At week four, 96.3%-100% of subjects had a ≥ 1-grade improvement with ABO 50-125 U doses; at week 24, 65.0%-67.9%; and at week 36, 33.8%-44.4%. Response rates based on GAIS and FACE-Q appraisal of lines showed a similar pattern of change.
Participants reported high satisfaction and noted a more natural and youthful appearance, alongside improvements in psychological well-being.